[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2014/135876,2014,A1Locationinpatent:Page/Pagecolumn43-45
[2]CurrentPatentAssignee:ASTRAZENECAPLC-US2014/255428,2014,A1Locationinpatent:Paragraph0253-0254
[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2014/135876,2014,A1
[2]CurrentPatentAssignee:ASTRAZENECAPLC-US2014/255428,2014,A1
[1]CurrentPatentAssignee:ASTRAZENECAPLC-WO2014/135876,2014,A1
[2]CurrentPatentAssignee:ASTRAZENECAPLC-US2014/255428,2014,A1
[1]Patent:WO2014/135876,2014,A1
[2]Patent:US2014/255428,2014,A1
[3]JournalofMedicinalChemistry,2015,vol.58,p.8200-8215
[4]Patent:CN109438423,2019,A
[1]Patent:WO2014/135876,2014,A1
[2]Patent:US2014/255428,2014,A1
[3]Patent:CN109438423,2019,A
Title: Zeng Q, et al. Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J Med Chem. 2015 Oct 22;58(20):8200-15.